Treatment for Caregiver Stress

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Dartmouth Hitchcock Medical Center, Dartmouth Centers for Health and Aging, Lebanon, NH
Caregiver Stress
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

To determine the effectiveness of the Self-care Sampler for Family Care Partners program in reducing caregiver stress over the 6-week program period. Hypothesis: Participants who attend the 6 class sessions over 6 weeks of the program will have a lower score on the Modified Caregiver Strain Index (MCSI) when compared to baseline. This will indicate a decrease in overall stress.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Baseline, week 1 change Post-Intervention, week 6

Week 6
Stress, as measured by Modified Caregiver Strain Index change

Trial Safety

Trial Design

0 Treatment Group

45 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, week 1 change post-intervention, week 6

Trial Background

Ellen Flaherty, Vice President Geriatric Center of Excellence, Principal Investigator
Principal Investigator
Dartmouth-Hitchcock Medical Center
Closest Location: Dartmouth Hitchcock Medical Center, Dartmouth Centers for Health and Aging · Lebanon, NH
N/AFirst Recorded Clinical Trial
1 TrialsResearching Caregiver Stress
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References